PMID- 24566861
OWN - NLM
STAT- MEDLINE
DCOM- 20150120
LR  - 20171116
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 21 Suppl 3
DP  - 2014 Jun
TI  - Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule 
      are linked with aggressive local recurrence of hepatocellular carcinoma after 
      radiofrequency ablation therapy.
PG  - S436-42
LID - 10.1245/s10434-014-3575-z [doi]
AB  - BACKGROUND: Radiofrequency ablation (RFA) is a widely used therapy for 
      hepatocellular carcinoma (HCC). Several reports have demonstrated the aggressive 
      local recurrence of HCC after RFA, suggesting that induction of further malignant 
      transformation of HCC has occurred. METHODS: Eighty-eight (88) patients with HCC 
      who underwent hepatic resection were included in this study. Hepatectomy was 
      indicated for local recurrence of HCC after RFA (n = 10, RFA group) and for HCC 
      without prior RFA (n = 78, non-RFA group). Clinicopathological data and the 
      patient's prognosis after hepatectomy were compared between the two groups. 
      Expression levels of hypoxia-inducible factor-1 (HIF-1), epithelial cell adhesion 
      molecule (EpCAM), CD44, and vascular endothelial growth factor messenger RNA 
      (mRNA) in the tumor tissues were also examined. RESULTS: The RFA group showed 
      higher frequency of portal vein invasion and less tumor differentiation compared 
      with the non-RFA group (p < 0.05). Overall and disease-free survival rates in the 
      RFA group were significantly worse than those in the non-RFA group (p < 0.05). 
      HIF-1 and EpCAM mRNA expression levels in the RFA group were significantly higher 
      than those in the non-RFA group (p < 0.05). CONCLUSIONS: These results suggest 
      that local HCC recurrence after RFA shows an aggressive tumor phenotype and poor 
      prognosis through the enhanced expressions of HIF-1 and EpCAM in the residual HCC 
      tumors after insufficient or sub-lethal treatment by RFA.
FAU - Yamada, Shinichiro
AU  - Yamada S
AD  - Departments of Digestive and Pediatric Surgery, Institute of Health Biosciences, 
      University of Tokushima Graduate School, Tokushima City, Tokushima, Japan.
FAU - Utsunomiya, Tohru
AU  - Utsunomiya T
FAU - Morine, Yuji
AU  - Morine Y
FAU - Imura, Satoru
AU  - Imura S
FAU - Ikemoto, Tetsuya
AU  - Ikemoto T
FAU - Arakawa, Yusue
AU  - Arakawa Y
FAU - Kanamoto, Mami
AU  - Kanamoto M
FAU - Iwahashi, Shuichi
AU  - Iwahashi S
FAU - Saito, Yu
AU  - Saito Y
FAU - Takasu, Chie
AU  - Takasu C
FAU - Ishikawa, Daichi
AU  - Ishikawa D
FAU - Shimada, Mitsuo
AU  - Shimada M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20140225
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD44 protein, human)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (EPCAM protein, human)
RN  - 0 (Epithelial Cell Adhesion Molecule)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Aged
MH  - Antigens, Neoplasm/genetics
MH  - Biomarkers, Tumor/genetics
MH  - Carcinoma, Hepatocellular/*genetics/mortality/pathology/surgery
MH  - Case-Control Studies
MH  - *Catheter Ablation
MH  - Cell Adhesion Molecules/genetics
MH  - Combined Modality Therapy
MH  - Epithelial Cell Adhesion Molecule
MH  - Female
MH  - Follow-Up Studies
MH  - Hepatectomy
MH  - Humans
MH  - Hyaluronan Receptors/genetics
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*genetics
MH  - Liver Neoplasms/*genetics/mortality/pathology/surgery
MH  - Male
MH  - Neoplasm Recurrence, Local/*genetics/mortality/pathology/surgery
MH  - Neoplasm Staging
MH  - Neoplasm, Residual/diagnosis/mortality
MH  - Prognosis
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Rate
EDAT- 2014/02/26 06:00
MHDA- 2015/01/21 06:00
CRDT- 2014/02/26 06:00
PHST- 2013/10/20 00:00 [received]
PHST- 2014/02/26 06:00 [entrez]
PHST- 2014/02/26 06:00 [pubmed]
PHST- 2015/01/21 06:00 [medline]
AID - 10.1245/s10434-014-3575-z [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2014 Jun;21 Suppl 3:S436-42. doi: 10.1245/s10434-014-3575-z. Epub 
      2014 Feb 25.